Naoki Ogusu

发表

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

Tae-Hwan Kim, J. Wei, M. Kishimoto, 2021, Annals of the Rheumatic Diseases.

Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy

K. Oniki, K. Nakagawa, J. Saruwatari, 2015, Neuropsychiatric disease and treatment.

Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis

K. Oniki, K. Nakagawa, J. Saruwatari, 2015, PloS one.

Impact of the Superoxide Dismutase 2 Val16Ala Polymorphism on the Relationship between Valproic Acid Exposure and Elevation of γ-Glutamyltransferase in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis

K. Oniki, J. Saruwatari, S. Kaneko, 2014, PloS one.

OP0234 EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Tae-Hwan Kim, M. Kishimoto, Shigeto Kobayashi, 2019, Oral Presentations.

Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang

Tae-Hwan Kim, M. Kishimoto, Shigeto Kobayashi, 2021, Annals of the Rheumatic Diseases.

Effects of CYP2C19 and P450 Oxidoreductase Polymorphisms on the Population Pharmacokinetics of Clobazam and N-Desmethylclobazam in Japanese Patients With Epilepsy

K. Nakagawa, J. Saruwatari, S. Kaneko, 2014, Therapeutic drug monitoring.

Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis

N. Yasui-Furukori, K. Oniki, J. Saruwatari, 2016, Pharmacogenetics and genomics.

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

J. Saruwatari, S. Tsuchimine, Naoki Ogusu, 2014, Pharmacogenomics and personalized medicine.

Pregnane X receptor and hepatocyte nuclear factor 4&agr; polymorphisms are cooperatively associated with carbamazepine autoinduction

K. Oniki, K. Nakagawa, J. Saruwatari, 2014, Pharmacogenetics and genomics.

Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases

K. Oniki, K. Nakagawa, J. Saruwatari, 2012, Epilepsy Research.